Antibiotic prophylaxis with meropenem after allogeneic stem cell transplantation

Area of Science:

• Hematology
• Infectious Diseases
• Transplant Medicine

Background:

• Allogeneic hematopoietic stem cell transplantation (HSCT) carries a high risk of infection and febrile episodes due to profound neutropenia.
• Empirical antibiotic therapy is standard, but strategies to reduce antibiotic exposure and associated resistance are crucial.

Purpose of the Study:

• To evaluate the efficacy of prophylactic meropenem administration in patients undergoing matched related donor allogeneic transplantation.
• To compare outcomes between early meropenem treatment initiation versus prophylactic use during neutropenia.

Main Methods:

• A pilot study involving 38 patients undergoing allogeneic transplantation.
• Patients were divided into two groups: Group A received meropenem upon the first febrile episode, while Group B received prophylactic meropenem starting with granulocyte counts <500/mm³.
• Treatment continued until fever resolution or granulocyte recovery >500/mm³.

Main Results:

• Fever developed in 94% of Group A patients versus 76% in Group B (P=0.02).
• Significantly fewer patients in Group B required first-line (33% vs. 6%) and second-line (52% vs. 11%) antibiotic therapy compared to Group A (P=0.01 and P=0.04, respectively).
• Multivariate analysis indicated that meropenem prophylaxis (HR=2.83) and early disease status at transplant (HR=0.15) were significant factors influencing fever development.

Conclusions:

• Prophylactic meropenem administration during neutropenia in allogeneic transplant recipients appears to favorably impact procedural morbidity.
• This strategy may reduce the incidence of febrile episodes and the need for broad-spectrum antibiotic use.
• Further prospective studies are warranted to confirm these findings.